Ultragenyx Pharmaceutical Inc. (RARE)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE). Investors who purchased Ultragenyx securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Ultragenyx has violated federal securities laws.
Ultragenyx Investigation Details
During pre-market hours on December 29, 2025, Ultragenyx announced results from two Phase 3 studies for setrusumab, a treatment for conditions impacting bone metabolism. Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively. Both studies achieved their secondary endpoints of improvements in bone mineral density against comparators (placebo and bisphosphonates) with strong statistical significance. There was no change in the safety profile observed. On this news, Ultragenyx’s stock price fell $2.02 per share, or 87.64%, to close at $0.28 on December 29, 2025.
What’s Next for Ultragenyx Investors?
If you are aware of any facts relating to this investigation or purchased Ultragenyx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/RARE. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Ultragenyx Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Ultragenyx Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.